

**For Immediate Release**

## **DIMERIX CHANGE OF ADDRESS AND CONTACT DETAILS**

MELBOURNE, Australia, 12 November 2018: Dimerix Limited (ASX: DXB) advises that in accordance with ASX Listing Rule 3.14, from today the address of its registered office, place of business and mailing address has changed to:

Address: 425 Smith Street, Fitzroy 3065, Victoria  
Telephone: 1300 813 321  
Website: [www.dimerix.com](http://www.dimerix.com)  
Email: [investor@dimerix.com](mailto:investor@dimerix.com)

For further information, please visit our website at [www.dimerix.com](http://www.dimerix.com) or contact the individuals outlined below.

—END—

At the Company  
Dr Nina Webster Dimerix Limited  
Chief Executive Officer  
Tel: 1300 813 321  
E: [investor@dimerix.com](mailto:investor@dimerix.com)

Investor Relations  
Glen Zurcher IR Department  
Account Director  
Tel: +61 420 249 299  
E: [glen.zurcher@irdepartment.com.au](mailto:glen.zurcher@irdepartment.com.au)

### **About Dimerix Bioscience Pty Ltd**

Dimerix Limited's (ASX: DXB) wholly owned subsidiary Dimerix Bioscience Pty Ltd is a dynamic, clinical-stage drug development company, developing and commercialising patient-preferred and patent protected pharmaceutical products for global markets. Dimerix is currently developing its product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

For more information see [www.dimerix.com](http://www.dimerix.com)